Trevi Therapeutics
TRVI
32 hedge funds and large institutions have $80.8M invested in Trevi Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
146% more capital invested
Capital invested by funds: $32.9M → $80.8M (+$47.9M)
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
46.6% more ownership
Funds ownership: 27.72% → 74.31% (+47%)
39% more funds holding
Funds holding: 23 → 32 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$27.9M |
| 2 |
VA
VR Adviser
New York
|
+$7.49M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.37M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$3.99M |
| 5 |
ACM
Altium Capital Management
New York
|
+$3.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$1.23M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$52K |
| 3 |
Millennium Management
New York
|
-$45.9K |
| 4 |
VF
Virtu Financial
New York
|
-$44K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$33K |
TRVI Hedge Fund Activity: Q2 2022 in Review
32 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q2 2022, worth a combined $80.8M — up 146% from $32.9M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TRVI positions and 4 closed out — a net gain of 9 holders — while 12 added to existing stakes and 5 trimmed.
The largest buyer was NEA Management Company, adding an estimated $27.9M. The largest seller was TPG GP A, cutting an estimated $1.23M.
- 32 institutional investors held Trevi Therapeutics (TRVI) as of Q2 2022, up from 23 in Q1 2022.
- Funds reported $80.8M of Trevi Therapeutics stock for Q2 2022, up 146% quarter-over-quarter.
- 13 funds opened new Trevi Therapeutics positions in Q2 2022 and 4 closed out, a net change of +9 holders.
- The largest Trevi Therapeutics buyer in Q2 2022 was NEA Management Company, an estimated $27.9M added.
- The largest Trevi Therapeutics seller in Q2 2022 was TPG GP A, an estimated $1.23M sold.
Based on aggregated 13F filings for Q2 2022.